Todd Tushla
Vice President, Investor Relations
Replay available
Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q1 2025 earnings conference call, held 2025-05-05. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Kyle Gaino
Chief Executive Officer
Matt Abernathy
Chief Financial Officer
Eric Benevich
Chief Commercial Officer
Ivory Roberts
Chief Medical Officer
Paul Matias
Analyst, Stiefel
Tazeen Ahmad
Analyst, Bank of America
Phil Nadeau
Analyst, TD Cowen
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Neurocrine Biosciences, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.082 -- 00:00:05.447 Good day, everyone, and welcome to Neurocrine Biosciences Report's first 00:00:05.447 -- 00:00:08.170 quarter 2025 results. 00:00:08.170 -- 00:00:12.113 At this time, all participants are in a listen-only mode. 00:00:12.113 -- 00:00:17.278 Later, you will have the opportunity to ask questions during the question and answer 00:00:17.278 -- 00:00:18.840 session. 00:00:18.840 -- 00:00:23.504 Please note, today's call will be recorded, and I will be standing by should you need 00:00:23.504 -- 00:00:25.546 any assistance. 00:00:25.546 -- 00:00:29.917 It is now my pleasure to turn the conference over to Todd Tushla. 00:00:29.917 -- 00:00:35.202 Vice President of Investor Relations. Please go ahead. 00:00:36.346 -- 00:00:39.290 Thank you, and happy Cinco de Mayo to everyone. 00:00:39.290 -- 00:00:43.817 Welcome to Nurocrine Biosciences first quarter 2025 earnings call. 00:00:43.817 -- 00:00:48.804 With me today are Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial 00:00:48.804 -- 00:00:53.991 Officer, Eric Benevich, Chief Commercial Officer, and for one last time as Chief Medical 00:00:53.991 -- 00:00:59.482 Officer, Ivory Roberts. During today's call, we will be making forward-looking statements. 00:00:59.482 -- 00:01:03.447 These statements are subject to certain risks and uncertainties, and our actual results 00:01:03.447 -- 00:01:07.813 may differ materially. I encourage you to review the risk factors discussed in our latest 00:01:07.813 -- 00:01:12.679 SEC filings. Following prepared remarks, we will strive to get to everyone's questions. 00:01:12.679 -- 00:01:15.422 Now, I will turn the call over to Kyle. 00:01:15.422 -- 00:01:19.708 Thanks, Todd. Good afternoon, everyone. Nurocrin has never been in a stronger pos...